NEW YORK, June 10, 2019 /PRNewswire/ -- Hoth Therapeutics,
Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on unique
targeted therapeutics for patients suffering from indications such
as atopic dermatitis-also known as eczema-as well as dermatological
and chronic wound disorders, today announced it has signed
contracts with providers for production of their BioLexa
therapeutic, in preparation for upcoming toxicology and clinical
studies.
Hoth has begun preparations for the testing of its formulation
for both active and vehicle stability. The Company has
engaged the services of both Particle Sciences, Inc. and Regis
Technologies, Inc., in order to fulfill the necessary formulation
and production of both Good Laboratory Practice (GLP) and Good
Manufacturing Practice (GMP) of its biopharmaceutical. The
BioLexa Platform is a proprietary, patented antimicrobial therapy
designed for the treatment of atopic dermatitis. The therapeutic
offers a non-corticosteroid approach treating atopic
dermatitis.
"Management is extremely pleased to announce this significant
step in our developmental track," stated Robb Knie, CEO of
Hoth Therapeutics. "Atopic dermatitis often has a negative
impact on patients' overall health and quality of life.
Current treatments, such as topical corticosteroids and other
treatments frequently carry harsh side effects. Hoth looks
forward to initiating these clinical trials, as we believe that our
BioLexa therapeutic has the potential to become a much needed
treatment for this underserved market."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc.,
a Nevada corporation, is a biopharmaceutical company
focused on unique targeted therapeutics for patients suffering from
indications such as atopic dermatitis, also known as eczema. Hoth
has exclusive worldwide rights to the BioLexa Platform.
Forward Looking Statements
This press release includes
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to the advancement and development of the
BioLexa Platform, the commencement of clinical trials, the
availability of data from clinical trials and other information
that is not historical information. When used herein, words such as
"anticipate", "being", "will", "plan", "may", "continue", and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
Hoth's current expectations and various assumptions. Hoth believes
there is a reasonable basis for its expectations and beliefs, but
they are inherently uncertain. Hoth may not realize its
expectations, and its beliefs may not prove correct. Actual results
could differ materially from those described or implied by such
forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Hoth's Form
10K for the period ending December 31, 2018, and Hoth's other
filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
Contact
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original
content:http://www.prnewswire.com/news-releases/hoth-therapeutics-to-begin-production-of-biolexa-therapeutic-for-upcoming-toxicology-and-clinical-trials-300864323.html
SOURCE Hoth Therapeutics Inc.